Health TrialsbyHealthPanel

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

ConditionsLipodystrophyGeneralized Lipodystrophy (GLD)Monogenic Obesity (MOB)
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorRegeneron Pharmaceuticals

About this trial

Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • REGN4461

    Drug

    To be provided by Regeneron

Treatment groups

No treatment groups listed

Trial outcomes

This trial has no outcomes listed.

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Regeneron Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov
Apply now